|
|
|
| Human papillomavirus infection status among women in Deqing County |
| CHEN Jianyuan, XU Guoqin, YAO Yunlei
|
| Deqing Maternal and Child Health and Family Planning Service Center, Deqing, Zhejiang 313200, China |
|
|
|
|
Abstract Objective To analyze the infection status of human papillomavirus (HPV) among women aged 35-64 years in Deqing County, Zhejiang Province, so as to provide a reference for the prevention and treatment of cervical lesions. Methods Women aged 35-64 years who underwent combined cervical cancer screening with HPV and ThinPrep cytologic test (TCT) at the Deqing County Maternal and Child Health and Family Planning Service Center from 2022 to 2024 were selected as study participants. The HPV infection rate and subtype distribution, positive rate of epithelial cell abnormalities, and positive rate of cervical lesions were analyzed. Results A total of 16 155 women were included, with the 55-<60 years age group being the most prevalent, accounting for 8 200 (50.76%). HPV infection was detected in 2 015 cases, with an infection rate of 12.47%. High-risk HPV infection was detected in 1 735 cases (86.10%), with an infection rate of 10.74%. Low-risk HPV infection was detected in 280 cases (13.90%), with an infection rate of 1.73%. The top three HPV subtypes with the highest infection rates were HPV52, 58, and 16, with infection rates of 3.46%, 1.84%, and 1.18%, respectively. The rates of high-risk HPV infection, single infection, and multiple infection all showed an upward trend with increasing age (all P<0.05), peaking in the group aged 60-64 years, at 13.26%, 10.96%, and 2.30%, respectively. The positive rate of cervical epithelial cell abnormalities in women with high-risk HPV infection was higher than in women with low-risk HPV infection (27.43% vs. 2.86%, P<0.05). Among them, the positive rates of low-grade squamous intraepithelial lesions and atypical squamous cells of undetermined significance were higher in women with high-risk HPV infection than in women with low-risk HPV infection (both P<0.05). Cervical lesions were detected in 150 cases, with a positive rate of 8.65%. Conclusions The HPV infection rate among women aged 35-64 years in Deqing County was at a moderate level nationally, with HPV52, 58, and 16 being the predominant subtypes. The infection rate increases with age, highlighting the need for enhanced cervical lesions screening among women with high-risk HPV infection.
|
|
Received: 19 September 2025
Revised: 31 March 2026
Published: 21 April 2026
|
|
|
|
|
|
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. [2] 王丽萍,张月,孙滨州,等.120例女性宫颈病变患者HPV感染的基因型分布和病理特征分析[J].新发传染病电子杂志,2024,9(4):23-28. [3] 田野,潘宇,曹明杰.100例女性阴道微生态多样性、人乳头瘤病毒感染亚型分析及与宫颈病变的相关性研究[J].中国性科学,2022,31(7):67-71. [4] 白茂潮,李芬,地力努尔·吐尔逊,等.HPV感染女性焦虑症状的影响因素分析[J].预防医学,2025,37(6):573-576,582. [5] 伊丽达娜·米吉提,海尼古丽·玉苏蒲,刘海霞,等.1 195例女性HPV流行病学调查及宫颈病变风险评估[J].新疆医学,2023,53(9):1044-1048. [6] 许英慧,邓燕杰.关于宫颈病变患者HPV感染情况及阴道菌群变化的相关分析[J].中国微生态学杂志,2024,36(10):1231-1236. [7] 王临虹,赵更力.子宫颈癌综合防控指南[M].2版.北京:人民卫生出版社,2023. [8] ZHANG J Y,ZHA T Z,WANG X M,et al.Prevalence and genotype distribution of HPV infections among women in Chengdu,China[J/OL].Virol J,2024,21(1)[2026-03-31].https://doi.org/10.1186/s12985-024-02317-x. [9] 曾艳华,何文丽,孟存仁.乌鲁木齐地区不同民族女性HPV感染基因亚型分布分析[J].国际检验医学杂志,2020,41(14):1769-1772. [10] 唐凤祝,简洁,梁开如,等.21 776例女性人乳头瘤病毒感染情况及亚型分布与宫颈细胞病变的相关性分析[J].中国计划生育和妇产科,2021,13(5):92-96. [11] 韩思蕊. 中国女性HPV的感染状况:基于273万例样本的流行病学调查[D].汕头:汕头大学,2025. [12] 范永霞,王英,刘春燕,等.成都市9 142例女性HPV感染状况、亚型分布及与宫颈病变的关系分析[J].肿瘤预防与治疗,2020,33(7):584-589. [13] 徐岚岚,黄芝,吴智华,等.高危HPV亚型感染特点与宫颈病变风险的相关性[J].药物生物技术,2025,32(3):284-289. [14] RAYNER M,WELP A,STOLER M H,et al.Cervical cancer screening recommendations:now and for the future[J/OL].Healthcare (Basel),2023,11(16)[2026-03-31].https://doi.org/10.3390/healthcare11162273. [15] ZHANG Y Y,NI Z W,WEI T,et al.Persistent HPV infection after conization of cervical intraepithelial neoplasia:a systematic review and meta-analysis[J/OL].BMC Womens Health,2023,23(1)[2026-03-31].https://doi.org/10.1186/s12905-023-02360-w. |
|
|
|